Major Depressive Disorder is a significant and costly cause of global disability. Until the 16 discovery of the rapid acting antidepressant (RAAD) effects of ketamine, treatments were 17 limited to drugs that have delayed clinical benefits. The mechanism of action of ketamine is 18 currently unclear but one hypothesis is that it may involve neuropsychological effects 19 mediated through modulation of affective biases. Previous work has shown that affective 20 biases in a rodent decision-making task are differentially altered by ketamine, compared to 21 conventional, delayed onset antidepressants. This study sought to further investigate these 22 effects by comparing ketamine with other NMDA antagonists using this decision-making 23 task. We also investigated the subtype selective GluN2B antagonist, CP-101,606 and 24 muscarinic antagonist scopolamine which have both been shown to have RAAD effects. 25
Introduction
4 blocker developed for the treatment of MDD, but failed to show efficacy in clinical trials 17 ; 62 memantine, an Alzheimer's medication that is a moderate affinity, non-competitive NMDA 63 receptor antagonist, but also lacked antidepressant efficacy in clinical trials 5, 18 ; and MK-801, 64 a potent, non-competitive NMDA receptor antagonist that has shown RAAD efficacy in 65 animal models 19 . We also tested other compounds that have been shown to have RAAD in 66 human clinical trials: the GluN2B subunit selective NMDA receptor antagonist CP-101,606 20 , 67 and the acetylcholine muscarinic receptor antagonist scopolamine 21 . We also tested 68 additional doses of ketamine and PCP to ensure we had examined effects across a wider 69 range of receptor occupancy and in line with doses commonly used in preclinical animal 70 models used to study depression 22 . To investigate the mechanism underlying the rapid 71 positive change in decision-making bias we tested local administration of drugs shown to 72 cause this effect directly into the prefrontal cortex (PFC), a brain area thought to be critical in 73 the mechanism of RAAD of ketamine 23, 24 and previously shown to modulate learning biases 74 in rodents 25 . 75 6 Judgement bias testing 102
Baseline sessions (100 trials: 50 high and 50 low reward tones; presented pseudorandomly) 103
were conducted on Monday and Thursday. Probe test sessions (120 trials: 40 high reward, 104 40 low reward, and 40 ambiguous midpoint tones that were 5kHz at 75dB; pseudorandomly) 105 were conducted on Tuesday and Friday. The midpoint tone was randomly reinforced so that 106 a specific outcome could not be learnt, and to maintain responding throughout the 107 experiments. Cohort 1 were used to test the effect of acute systemic treatments with putative 108 RAAD and other NMDA receptor antagonists. Cohort 2 were made up of two groups of eight 109 rats that had previously been used as control animals in another experiment (data not 110 shown) and were then used for the extension of doses of ketamine and PCP. Cohort 3 were 111 used for mPFC infusion experiments. For further details see Table S2 . 112
Study 1: the effect of acute, systemic treatments with RAADs and NMDA receptors 113
antagonists on judgement bias. 114
Experimental design: Each study used a within-subject fully counterbalanced drug 115 treatment schedule (see Table S2 for details of individual treatments). All drugs were given 116 by intraperitoneal injection using a low-stress, non-restrained technique 26 . Ketamine ¥ 117 (Sigma-Aldrich, UK), scopolamine § (Tocris, UK), lanicemine ¥ (Sigma Aldrich, UK), 118 memantine ¥ (Tocris, UK), MK-801 § (Tocris, UK) and PCP ¥ (Sigma Aldrich, UK) were 119 dissolved in 0.9% sterile saline and given 30 § or 60 ¥ minutes prior to testing. CP-101,606 120 (Experiment 1: Sigma Aldrich, UK; Experiment 2: Boehringer Ingelheim GmbH) was 121 dissolved in 5% DMSO, 10% cremaphor and 85% sterile saline and given 60 minutes prior 122 to testing. Drug doses were selected based on previous rodent behavioural studies 16, 28 . 123
Doses for ketamine and PCP were chosen to extend the range of doses tested in this task 124 e.g. higher doses of ketamine and lower doses of PCP were used than previously 16 . For all 125 studies, the experimenter was blind to drug dose. Each dose-response study was separated 126 by at least one week (five sessions) of baseline testing. The order of testing is displayed in 127 Table S2 . 128 8 the low reward lever from the proportion of responses made on the high reward lever. This 155 created a score between -1 and 1, where negative values represent a negative bias and 156 positive values a positive bias. Change from baseline in CBI was then calculated for all 157 experimental manipulations as follows: vehicle (0.0mg/kg) probe test CBI − drug dose probe 158 test CBI. This was calculated to take into account individual differences in baseline bias, and 159 to make directional changes caused by drug treatments clearer. To provide a value for 160 vehicle probe test sessions for this measure, the population average for the vehicle 161 (0.0mg/kg) probe test was taken away from each individual rats' CBI score for the same 162 session. This allowed this measure to be analysed with repeated measures analysis of 163 variance (rmANOVA) with session as the within-subjects factor for drug studies with more 164 than two treatments, or paired samples t-test for studies with only two treatments. 165
Response latency and accuracy, omissions and premature responses were also analysed 166 (see Table S3 for details of these). These measures were analysed with rmANOVAs with 167 session and tone as the within-subjects factors. Paired t-tests were performed as post-hoc 168 tests if significant effects were established. Huynh-Feldt corrections were used to adjust for 169 violations of the sphericity assumption, and Sidak correction was applied for multiple 170 comparisons. All statistical tests were conducted using SPSS 24.0.0.2 for Windows (IBM 171 SPSS Statistics) with α=0.05. Results are reported with the ANOVA F-value (degrees of 172 freedom, error) and p-value as well as any post-hoc p-values. All graphs were made using 173 Graphpad Prism 7.04 for Windows (Graphpad Software, USA). 174 sample t-test: p=0.038; Figure 1A ). In the second experiment, CP-101,606 (6.0mg/kg) 181 resulted in a positive bias relative to vehicle treatment (paired samples t-test: p=0.027; 182 Figure 1A ). In experiment 1, 3.0mg/kg CP-101,606 also caused a decrease in response 183 latency for the midpoint tone (main effect of session: F 3,42 =4.858, p=0.005, post-hoc: 184 p=0.048; Table 1) , with a trend towards the same effect for the low tone (post-hoc: p=0.076; 185 Table 1 ). There were no effects on other behavioural measures in experiment 1 ( Table 1 ). In 186 experiment 2, CP-101,606 (6.0mg/kg) caused response latencies to decrease for all three 187 tones (main effect of session: F 1,14 =27.396, p<0.001, post-hoc: ps≤0.005; Table 1 ). This 188 dose had no effect on accuracy for the reference tones (Table 1) , but did increase premature 189 responses (paired samples t-test: p=0.001), and reduced omissions (main effect of session: 190 F 1,14 =10.506, p=0.006; Table 1 ) for the midpoint (p=0.008) and low tones (p=0.024; Table 1 ). 191
Scopolamine: The highest dose tested (0.3mg/kg) had to be excluded from the analysis as 192 most rats did not complete sufficient trials. Scopolamine (0.1mg/kg) induced a positive bias 193 (main effect of session: F 2,30 =6.739, p=0.004, post-hoc: p=0.035; Figure 1B ). This dose of 194 scopolamine (0.1mg/kg) also increased response latencies for all three tones (main effect of 195 session: F 2,30 =17.263, p<0.001, post-hoc: ps≤0.011; p=0.011, main effect of session: F 2,30 =24.257, p<0.001, post-hoc: ps<0.001; Table 1 ). The 199 lower dose also caused response latencies to increase for all tones (post-hoc: ps≤0.001; 200 Table 1 ), accuracy to increase for the low tone only (main effect of session: 10 F 1.605,24.069 =8.558, p=0.003, post-hoc: p=0.004; Table 1) , and omissions to increase for all 202 tones (post-hoc: ps≤0.019; Table 1 ). 203
Ketamine: In the rats who had undergone mPFC cannulation surgery, ketamine (1.0mg/kg) 204 caused a positive change in CBI (paired samples t-test: p=0.033; Figure 1C ), as has been 205 seen previously 16 . Ketamine did not alter any other behavioural measures (Table 1) . 206
Lanicemine: None of the doses of lanicemine tested caused a change in CBI ( Figure 1D) . 207
This drug also had no effect on any other behavioural measures ( Table 1) . 208
Memantine: Memantine did not cause any change in CBI at the doses tested ( Figure 1E) . 209
There was also no effect on other behavioural measures ( Table 1) . 210 MK-801: MK-801 did not change CBI ( Figure 1F ). The highest dose of MK-801 tested 211 (0.03mg/kg) decreased response latency for the midpoint tone (main effect of session: 212 F 2,30 =3.843, p=0.033, post-hoc: p=0.013; Table 1 ) and also had a tendency to cause 213 premature responses to increase (trend towards main effect of session: F 1.565,23.480 =2.915, 214 p=0.085, post-hoc: p=0.039; Table 1 ). There was no effect on accuracy for the reference 215 tones or percentage omissions. 216
High-dose ketamine:
In experiment 2 (25mg/kg ketamine) one rat was excluded for failure 217 to complete sufficient trials. In experiments 1 and 2, ketamine (10mg/kg and 25mg/kg 218 respectively) did not change CBI (Figure 2A ). In both experiments these higher doses did 219 alter all other behavioural measures. There was an increase in response latency across all 220 three tones for both 10mg/kg (session*tone interaction: F 2,30 =7.323, p=0.003, post-hoc: 221 ps<0.001 for all tones; Figure 2B ), and 25mg/kg ketamine (session*tone interaction: 222 F 2,28 =4.686, p=0.018, post-hoc: ps≤0.002 for all tones; Figure 2B ). Both doses decreased 223 premature responses (paired samples t-tests: 10mg/kg -p=0.005, 25mg/kg -p=0.006; 224 Figure 2C ). Ketamine also improved accuracy for the low reward tone only in experiment 1 225 (10mg/kg: main effect of session: F 1,15 =8.774, p=0.010, and trend towards session*tone 226 interaction: F1,15=3.665, p=0.075, post-hoc: p=0.022; Figure 2D ) and experiment 2 227 (25mg/kg: trend towards main effect of session: F 1,14 =4.500, p=0.052, and session*tone 228 interaction: F1,14 = 5.513, p=0.034, post-hoc: p=0.033; Figure 2D ). In both experiments, 229 there was an increase in omissions for all three tones (experiment 1, 10mg/kg: session*tone 230 interaction: F 1.401,21.021 =5.662, p=0.018, post-hoc: high reward tone -p=0.015, midpoint tone: 231 p=0.003, low reward tone: p=0.010; experiment 2, 25mg/kg: session*tone interaction: 232 F 1.368,19.150 =11.964, p=0.001, post-hoc: high reward tone -p=0.003, midpoint tone -p<0.001, 233 low reward tone -p=0.001; Figure 2E ). 234
Low dose PCP: Doses of PCP (0.03, 0.1, 0.3mg/kg) that were lower than those previously 235 tested 16 did not cause any change in CBI ( Figure 1G ). There was also no effect on any other 236 behavioural measures (Table 1) . 237
238

Study 2: mPFC infusions of drugs shown to cause positive judgement biases 239
Two rats were excluded in cohort 3: one rat did not meet accuracy criteria for any probe (or 240 baseline) session following the second drug infusion; and after the end of testing another 241 animal was found to have an incorrect cannula placement. Therefore, both were excluded 242 retrospectively from the entire study. Compared to pre-surgery performance, the CBI of rats 243 became more negative after surgery, and this was stable across testing over three weeks 244 (main effect of week: F 3,42 =6.335, p=0.001, post-hoc: ps≤0.011; Figure 3A ). There were no 245 differences in response latencies, premature responses, accuracies for reference tones or 246 omissions before compared to after surgery (Table 1) . 247
In the first infusion experiment, ketamine (1.0μg/μl), muscimol (0.1μg/μl) and scopolamine 248 (0.1μg/μl) all induced positive biases (main effect of session: F 3,36 =7.241, p=0.001; post-hoc: 249 ketamine -p=0.012, muscimol -p=0.001, scopolamine -p=0.032 Figure 3C ). The effect of 250 PFC infusion of ketamine or scopolamine was specific to CBI, as these drugs had no effect 251 on other behavioural measures ( Figure 3D-G) , unlike muscimol infusions which caused 252 changes to all other behavioural measures. There was an increase in response latency 12 (session*tone interaction: F 6,72 =4.181, p=0.001) for the high reward (post-hoc: p<0.001) and 254 midpoint tone (p=0.028; Figure 3D ), and a large increase in premature responses to over 255 100% (main effect of session: F 1.151,13.809 =33.784, p<0.001, post-hoc: p<0.001; Figure 3E ). 256
Muscimol also caused accuracy to decrease for both reference tones (main effect of 257 session: F 1.181,14.172 =43.775, p<0.001, post-hoc: ps≤0.001; Figure 3F ). For the low reward 258 tone, this reduction was so great that rats were no longer performing any better than chance 259 (one-sample t-test against a test value of 50%: p=0.197; Figure 3F ). Omissions for the high 260 and low reward tones increased following muscimol infusion (main effect of session: 261 F 1.338,16.057 =10.418, p=0.003, post-hoc: high tone -p=0.010, low tone -p=0.012; Figure 3G) . 262
In the experiments testing the effect of CP-101,606 mPFC infusion, in experiment 1 the 263 lower dose (1.0μg/μl) did not alter CBI ( Figure 4A ), but in experiment 2, the higher dose 264
(3.0μg/μl) induced a positive bias (paired samples t-test: p=0.043; Figure 4A ). In experiment 265 1, CP-101,606 (1.0μg/μl) caused an increase in response latency for the midpoint tone only 266 (main effect of session: F 1,12 =5.064, p=0.044, post-hoc: p=0.019; Figure 4B measures. This suggests that the RAADs can modulate activity in this brain region in a more 286 specific way than muscimol, which results in a relatively specific effect on biases in decision-287
making. 288
For lanicemine and memantine, the lack of any behavioural effects means there is a 289 possibility that the doses tested were too low. However, for both of these the range of doses 290 tested covers the doses that are equivalent to those used humans in clinical trials 291 higher doses of ketamine than those we had previously, doses that have been shown to 297 have antidepressant effects in other preclinical models used to study depression 29 , we failed 298 to see any change in bias, instead only seeing non-specific changes in other behavioural 299 measures. This lends support to our interpretation that this reward-based judgement bias 300 task can specifically dissociate between drugs that do show RAAD, and those that do not, 301 despite them having similar pharmacology. 302
The difference in specificity on behavioural effects, whereby ketamine (1.0mg/kg) only 303 positively changes decision-making bias, but both CP-101,606 and scopolamine have other 304 non-specific effects, suggests that 1.0mg/kg ketamine is able to relatively selectively 305 modulate affective bias. The changes in response latencies, omissions and premature 306 responses caused by CP-101,606 and scopolamine suggest that these drugs may also be 307 having effects on other cognitive processes, such as motivation. However, the direction of 308 changes for these drugs are in opposite directions (decreases in response latency and 309 omissions for CP-101,606 but increases in these for scopolamine) despite them both 310 causing positive changes in CBI. This, combined with the lack of change in accuracy for the 311 reference tones, suggest that these non-specific effects cannot fully explain the change in 312 decision-making bias. 313
The neurobiology underlying the relative specificity of ketamine, CP-101,606 and 314 scopolamine in being able to immediately alter decision-making bias, in contrast to the other 315 NMDA receptor antagonists tested that have not shown these effects, are likely to be due to 316 differences in their mechanisms of action. Our findings add weight to the strong body of 317 evidence suggesting that NMDA receptor antagonism is important for short-term, RAAD 318 effects of these drugs 30 , but suggests that specific modulation of either a specific subtype of 319 the receptor or a sub-population of neurons may be involved. CP-101,606 is selective for the 320 GluN2B NMDA receptor subunit, whilst it has been shown that scopolamine, and more 321 recently ketamine, cause a glutamate burst via blockade of NMDA receptors specifically on 322 GABA interneurons that leads to increased mechanistic target of rapamycin complex 1 323
16
Final conclusions 350
This study adds to the evidence that the neuropsychological effects of ketamine are 351 potentially important in its RAAD in patients with MDD, and that these effects in altering 352 affective biases, both in decision-making as demonstrated here, as well as in learning and 353 memory occur at time points (one hour) before major plastic changes arise. It will be 354 important to investigate the neurobiological effects of not just the immediate, RAAD of 355 ketamine, but also the sustained effects by examining how affective biases are altered at 356 longer time points. Furthermore, investigation of the wider circuits involved in this RAAD 357 efficacy will be crucial in revealing the mechanism underlying these actions, which will be 358 important for the development of novel therapeutics. Ketamine (at 1.0 mg/kg) seems to have 359 very specific effects on affective bias, which we can capitalise on to better understand the 360 circuits that contribute to these modulations of affective biases that are potentially very 361 important in the cause, perpetuation and treatment of MDD. Probe tests with no experimental manipulation were conducted before and after mPFC 521 cannulation surgery to ensure that the surgery itself did not effect performance in the 522 
